Fulcrum Therapeutics (FULC) on Saturday reported positive initial results from its ongoing 20 mg dose cohort of the phase 1b PIONEER trial of pociredir in adult patients with sickle cell disease.

The company said that it observed clear dose-response, with a robust and clinically meaningful fetal hemoglobin induction at week 6 and mean absolute fetal hemoglobin in the 20 mg cohort increasing 9.9% at week 6 versus 5.6% in the 12 mg cohort.

The company further said that pociredir continued to be generally well-tolerated, with no treatment-related serious adverse events.

Fulcrum Therapeutics' share price jumped over 63% in recent Monday premarket activity.

Price: 14.55, Change: +5.65, Percent Change: +63.48